3 ms·
You're confusing two different things. When NICE decides not to fund something they have clear evidence that it is worse than current treatment, not just that
by DanBC 10y ago
You're confusing two different things.
When NICE decides not to fund something they have clear evidence that it is worse than current treatment, not just that it is more expensive than current treatment.
See, for example, Abraxane, a chemotherapy for pancreatic cancer.
To be accepted all it has to do is either:
i) Be better than current first line treatment or
ii) Have less side effects, and thus be usable as a second line treatment or
iii) Be much cheaper
It's fantastically expensive, has many side effects, and is less effective than current treatment. So it fails all three. But you wouldn't be able to tell that from the pharma-sponsored advocacy groups. Those groups talk about "2 years of life", when the manufacturer's own data talks of just 3 weeks.
It's incorrect to say that NICE has a profit motive. They very clearly - and this is the point of transparency - don't.
- chimeracoder 10y ago> You're confusing two different things. When NICE decides not to fund something they have clear evidence that it is worse than current treatment, not just that it is more expensive than current treatment. No, I'm not confusing two different things, and I'm glad you picked cancer as an example. Even if NICE has approved a treatment as "cost-effective", that doesn't mean that any specific patient will actually be eligible to receive it. For cancer treatments, there is a separate panel which reviews individual cases and provides the options available to that patient. It is not done on the aggregate; it's determined on the individual level. And, to make matters worse, if the patient decides to deviate sufficiently from the treatment plan (perhaps by delaying chemotherapy, or seeking treatment abroad first), those options can be rescinded, at which point the patient is required to pay out-of-pocket on the private market. > It's incorrect to say that NICE has a profit motive. They very clearly - and this is the point of transparency - don't. Every agency in every country, public or private, has a profit motive, and the DH is no exception. Transparency doesn't eliminate the profit motive; it just provides visibility into both the inputs and the outputs.
- refurb 10y agoWhen NICE decides not to fund something they have clear evidence that it is worse than current treatment, not just that it is more expensive than current treatment. That's not true at all. Kadcyla is superior to current therapies for HER+ breast cancer. NICE has decided not to fund it because it's too expensive.[1] But the reality is that the price of Kadcyla is currently too high in relation to the benefits it gives for it to be recommended for routine commissioning in the NHS, even taking into account the end‑of‑life criteria and the patient access scheme.” [1]https://www.nice.org.uk/news/article/kadcyla-too-expensive-for-routine-funding-on-nhs https://www.nice.org.uk/news/article/kadcyla-too-expensive-f...